Cross-sectional study reports intentional non-adherence to endocrine treatment in breast cancer survivors, indicating modification in interventions is necessary.
Although half of the patients reported not fully adhering to AET, only a small fraction missed enough doses to compromise treatment conduction. Distinguishing between subtypes of non-adherence and identifying modifiable factors such as AE and QoL issues, interventions can be tailored to meet the specific needs of patients, especially those at higher risk of non-adherence.
No takes yet. Share an insight, caveat, or question.
Okrosa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: